Synthetic Biologics Inc (SYN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Date: August 13, 2018
Pages: 48
Price:
US$ 250.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S777C6E317DEN
Leaflet:

Download PDF Leaflet

Synthetic Biologics Inc (SYN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Summary

Synthetic Biologics Inc (Synthetic Biologics), formerly Adeona Pharmaceuticals Inc is a clinical company that develops novel therapeutics to treat gut microbiome. The company’s pipeline products include SYN-004 and SYN-010. Its SYN-010 is a proprietary, modified-release formulation which is intended to treat rritable bowel syndrome with constipation. Synthetic Biologics’ SYN-004 is an oral prophylactic therapy for prevention of clostridium difficile infection, pathogenic overgrowth and the emergence of antimicrobial resistance. It develops preclinical monoclonal antibody therapies for the treatment of pertussis, and novel discovery stage biotherapeutics for the treatment of phenylketonuria. The company undertakes various research activities to develop therapeutics. It collaborates with various academic and pharmaceutical companies to develop its product candidates. Synthetic Biologics is headquartered in Rockville, Maryland, the US.

Synthetic Biologics Inc (SYN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope
  • Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
  • Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
  • Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
  • Key Competitors - A list of the key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.
Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
  • The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
  • The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
  • Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
  • Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
  • Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company.

NOTE: Out of security concerns GlobalData requires using corporate email address.
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Synthetic Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deal Details
Asset Purchase
Synthetic Biologics Completes Acquisition Of C. difficile Infectious Disease Program Of Prev AbR
Venture Financing
SeeChange Health Raises US$3 Million In Venture Financing
Partnerships
Synthetic Biologics Enters into Research Agreement with Centers for Disease Control and Prevention
Intrexon Enters into Partnership with Synthetic Biologics
Synthetic Biologics Exapnds its Agreement With Intrexon To Develop Monoclonal Antibodies For Infectious Diseases
Licensing Agreements
Synthetic Biologics Enters Into Licensing Agreement With Cedars-Sinai Medical Center
Equity Offering
Synthetic Biologics Plans to Raise up to USD200 Million in Public Offering of Shares
Synthetic Biologics Raises USD12 Million in Private Placement of Series A Preferred Shares
Synthetic Biologics Raises USD25 Million in Public Offering of Common Stock and Warrants
Synthetic Biologics Raises USD46 Million in Public Offering of Shares
Synthetic Biologics Raises USD20.7 Million in Private Placement of Units
Synthetic Biologics Completes Public Offering Of Shares For US$13.2 Million
Synthetic Biologics Completes Private Placement Of Common Stock For US$11 Million
Acquisition
Hartlab Acquires Adeona Clinical Lab From Synthetic Biologics
Synthetic Biologics Inc - Key Competitors
Synthetic Biologics Inc - Key Employees
Synthetic Biologics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Financial Announcements
May 08, 2018: Synthetic Biologics Reports First Quarter 2018 Operational Highlights And Financial Results
Feb 22, 2018: Synthetic Biologics Reports 2017 Year End Operational Highlights and Financial Results
Nov 01, 2017: Synthetic Biologics Reports Third Quarter 2017 Operational Highlights and Financial Results
Aug 03, 2017: Synthetic Biologics Reports Second Quarter 2017 Operational Highlights and Financial Results
May 04, 2017: Synthetic Biologics Reports First Quarter 2017 Operational Highlights and Financial Results
Mar 02, 2017: Synthetic Biologics Reports 2016 Year End Operational Highlights and Financial Results
Corporate Communications
May 22, 2018: Synthetic Biologics Announces Acceptance of Compliance Plan by NYSE American
Mar 07, 2018: Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan
Dec 05, 2017: Synthetic Biologics Announces Management Changes
Product News
01/18/2017: Synthetic Biologics Confirms Key Features of Pivotal Phase 2b/3 Trial of SYN-010 Pursuant to Consultations with FDA
Clinical Trials
Apr 19, 2017: Synthetic Biologics Reports Preclinical Data Demonstrating SYN-005 Provides Protection from Pertussis in Neonatal Animal Study
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Synthetic Biologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018
Synthetic Biologics Inc, Deals By Therapy Area, 2012 to YTD 2018
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018
Synthetic Biologics Completes Acquisition Of C. difficile Infectious Disease Program Of Prev AbR
SeeChange Health Raises US$3 Million In Venture Financing
Synthetic Biologics Enters into Research Agreement with Centers for Disease Control and Prevention
Intrexon Enters into Partnership with Synthetic Biologics
Synthetic Biologics Exapnds its Agreement With Intrexon To Develop Monoclonal Antibodies For Infectious Diseases
Synthetic Biologics Enters Into Licensing Agreement With Cedars-Sinai Medical Center
Synthetic Biologics Plans to Raise up to USD200 Million in Public Offering of Shares
Synthetic Biologics Raises USD12 Million in Private Placement of Series A Preferred Shares
Synthetic Biologics Raises USD25 Million in Public Offering of Common Stock and Warrants
Synthetic Biologics Raises USD46 Million in Public Offering of Shares
Synthetic Biologics Raises USD20.7 Million in Private Placement of Units
Synthetic Biologics Completes Public Offering Of Shares For US$13.2 Million
Synthetic Biologics Completes Private Placement Of Common Stock For US$11 Million
Hartlab Acquires Adeona Clinical Lab From Synthetic Biologics
Synthetic Biologics Inc, Key Competitors
Synthetic Biologics Inc, Key Employees
Synthetic Biologics Inc, Subsidiaries

LIST OF FIGURES

Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018
Synthetic Biologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018
Skip to top


Ask Your Question

Synthetic Biologics Inc (SYN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: